HK1014190A1 - Pharmacotherapeutical use of glutathione derivatives - Google Patents

Pharmacotherapeutical use of glutathione derivatives

Info

Publication number
HK1014190A1
HK1014190A1 HK98115451A HK98115451A HK1014190A1 HK 1014190 A1 HK1014190 A1 HK 1014190A1 HK 98115451 A HK98115451 A HK 98115451A HK 98115451 A HK98115451 A HK 98115451A HK 1014190 A1 HK1014190 A1 HK 1014190A1
Authority
HK
Hong Kong
Prior art keywords
glutathione
pharmacotherapeutical
many disorders
glutathione derivatives
ester
Prior art date
Application number
HK98115451A
Inventor
Gerhard Ohlenschlaeger
Original Assignee
Gerhard Ohlenschlaeger
Treusch Gernot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerhard Ohlenschlaeger, Treusch Gernot filed Critical Gerhard Ohlenschlaeger
Publication of HK1014190A1 publication Critical patent/HK1014190A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)

Abstract

Two glutathione thiol derivatives, namely the monomethyl ester and the monoethyl ester of reduced glutathione, are proposed for use as medicaments for a wide range of different indications, also in combination with vitamins, an amino acid or a substance which contains a semiconductor element in inorganically or organically bound form. The proposal is based on the knowledge that many disorders of cell metabolism can be rectified by glutathione therapy and therefore many disorders which are accompanied or caused by the loss of the reductive potential can be cured.
HK98115451A 1987-07-09 1998-12-24 Pharmacotherapeutical use of glutathione derivatives HK1014190A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873722647 DE3722647A1 (en) 1987-07-09 1987-07-09 GALENIC USE OF A TRIPEPTID AS A MEDICINAL PRODUCT

Publications (1)

Publication Number Publication Date
HK1014190A1 true HK1014190A1 (en) 1999-09-24

Family

ID=6331195

Family Applications (2)

Application Number Title Priority Date Filing Date
HK74697A HK74697A (en) 1987-07-09 1997-06-05 Pharmaceutical therapeutic use of glutathione derivatives
HK98115451A HK1014190A1 (en) 1987-07-09 1998-12-24 Pharmacotherapeutical use of glutathione derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK74697A HK74697A (en) 1987-07-09 1997-06-05 Pharmaceutical therapeutic use of glutathione derivatives

Country Status (8)

Country Link
EP (2) EP0655460B1 (en)
JP (3) JP2851289B2 (en)
AT (2) ATE121942T1 (en)
AU (1) AU1994488A (en)
DE (1) DE3722647A1 (en)
HK (2) HK74697A (en)
LV (1) LV5793B4 (en)
WO (1) WO1989000427A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
JP2815179B2 (en) * 1989-07-14 1998-10-27 千寿製薬株式会社 Anti-inflammatory and / or anti-allergic agent
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
JP2919867B2 (en) * 1989-09-27 1999-07-19 千寿製薬株式会社 Antitumor agent
JP2919870B2 (en) * 1989-09-29 1999-07-19 千寿製薬株式会社 Liver damage inhibitor
KR970002904B1 (en) * 1990-04-26 1997-03-12 센쥬 세이야꾸 가부시끼가이샤 S-(lower fatty acid)-substituted glutathione derivative
EP0545972B1 (en) * 1990-08-20 1994-11-02 Gerhard Dr. med. OHLENSCHLÄGER Therapeutically active mixture of glutathion and anthocyan compounds
FR2683722B1 (en) * 1991-11-14 1995-05-24 Arkopharma Laboratoires MEDICAMENT FOR THE BASIC TREATMENT OF BETA-CAROTENE-BASED ASTHMA.
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
CA2134239C (en) * 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
TW225992B (en) * 1992-07-17 1994-07-01 Senju Pharma Co
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
DE4329857C2 (en) 1993-09-03 1995-08-24 Deutsches Krebsforsch Connection to strengthen the immune system and immune reactions
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
US6337320B1 (en) * 1996-10-11 2002-01-08 Thione International, Inc. Reparatives for ultraviolet radiation skin damage
US6194457B1 (en) * 1997-01-29 2001-02-27 A. Glenn Braswell Liquid eye drop composition
ES2185576T3 (en) 1999-02-22 2003-05-01 Gernot Treusch MIXTURE OF THERAPEUTIC ACTION SUBSTANCES CONTAINING S-ACETILGLUTATION AND ACICLOVIR.
FR2804126B1 (en) * 2000-01-21 2005-09-30 Patrick Rambaud METHOD AND SYSTEM FOR MANAGING LOTS OF IMMUNO-COMPETENT CELLS FROM HUMAN OR ANIMAL SUBJECTS FOR DELAYED USES
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
US6881396B2 (en) 2000-10-24 2005-04-19 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
ES2282326T3 (en) * 2000-10-24 2007-10-16 Cis Bio International STABILIZATION OF RADIO-PHARMACEUTICAL COMPOSITIONS USING HYDROPHYLIC OR 6-HYDROXYCHROMANIC HYDROXYCLAN THIOETHERS.
DE10210427A1 (en) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Human monoclonal antibody
EP1521776A2 (en) 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
US20070244304A1 (en) 2003-11-12 2007-10-18 Oncomab Gmbh Methods of Identifying Neoplasm-Specific Antibodies and Uses Thereof
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
EP2233137B1 (en) * 2005-11-09 2014-04-30 Ajinomoto Co., Inc. Calcium receptor activator
JP2013035772A (en) * 2011-08-05 2013-02-21 Osaka City Univ Leukocyte activation inhibitor
EP2874640A4 (en) * 2012-01-05 2016-10-26 Frederick Timothy Guilford Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
NZ706329A (en) * 2012-09-28 2018-06-29 Kyowa Hakko Bio Co Ltd Agent for enhancing immunity containing glutathione
ITMI20131856A1 (en) * 2013-11-08 2015-05-09 Gnosis Spa PROCESS FOR THE PREPARATION OF DIFFERENT CRYSTALLINE FORMS OF S-ACETYL GLUTATHY AND THEIR USE IN PHARMACEUTICAL AND NUTRACEUTICAL FORMULATIONS
DE202013010690U1 (en) 2013-11-27 2014-04-10 Erhard Römer Pharmaceutical and therapeutic uses of G-SH (reduced glutathione), SAG (S-acetyl-glutathione) also in the micronized range of 1 to 200 my and 1 to 200 nm
DE102014002913A1 (en) 2014-03-03 2015-09-03 Conrad Leuthaeuser Preparation of a micronization of S-acetylglutathione of a pharmaceutical therapeutic substance with a pilot grinding of 1 <100 μm (micron)
IT202100031985A1 (en) * 2021-12-21 2023-06-21 Innbiotec Pharma S R L PHARMACEUTICAL COMPOSITION BASED ON GLUTATHIE THIOESTER AND OLEUROPEIN FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STATEATOHEPATITIS
CN116037240B (en) * 2022-11-25 2023-08-01 杭州皓丰生物技术有限公司 A liquid-transfering gun head for suspending quick liquid of cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB144404A (en) * 1919-03-21 1920-06-17 Alexander James Ernest Geairns Improvements in fuel and air supplying arrangements for internal combustion engines
US1444024A (en) * 1920-08-31 1923-02-06 John S Burdick Adjustable seat
GB1444024A (en) * 1973-07-20 1976-07-28 Passwaterr A Food and feed supplents
DE2813814A1 (en) * 1978-03-31 1979-10-18 Boehringer Mannheim Gmbh Increasing the enteral reabsorption of pharmaceuticals - by administration together with an aminoacid or a peptide
RO79426B1 (en) * 1982-02-23 1984-07-30 Romulus Constantin Dinu Medicinal composition for treating neuroviroses
JPH0695945B2 (en) * 1986-10-09 1994-11-30 マルハ株式会社 Acetyl CoA manufacturing method

Also Published As

Publication number Publication date
AU1994488A (en) 1989-02-13
ATE188968T1 (en) 2000-02-15
EP0327612B1 (en) 1995-05-03
WO1989000427A1 (en) 1989-01-26
HK74697A (en) 1997-06-13
EP0327612A1 (en) 1989-08-16
JPH11147836A (en) 1999-06-02
JPH11106349A (en) 1999-04-20
JPH02500841A (en) 1990-03-22
LV5793B4 (en) 1997-04-20
JP2851289B2 (en) 1999-01-27
ATE121942T1 (en) 1995-05-15
EP0655460B1 (en) 2000-01-19
EP0655460A1 (en) 1995-05-31
DE3722647A1 (en) 1989-01-19
LV5793A4 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
HK1014190A1 (en) Pharmacotherapeutical use of glutathione derivatives
DK69090A (en) Connector piece with Y-shape for use in angioplasty
ES8800945A1 (en) 8-Phenyl xanthines.
GR3018541T3 (en) Condensed heterocyclic compounds and their use in therapy.
GB2193029B (en) Training device for practicing emergency life saving techniques.
HU894712D0 (en) Instrument for diagnosing and curing the illnesses of nose
NO165627C (en) ABSORPENTS CONTAINING A STRONGLY DISABLED AMINO COMPOUND AND AN AMINAL AND PROCEDURE FOR ABSORPTION HAVE BY USING THEREOF.
DK435888D0 (en) PROCEDURE FOR ASSEMBLING A BODY IN A FLUID CONDUCT, AND APPARATUS FOR EXERCISING THE PROCEDURE
EP0207773A3 (en) 7-û(substituted)amino¨-8-û(substituted)carbonyl)-methylamino¨-1-oxaspiroû4.5¨decanes as analgesic agents
FR2592388B1 (en) POLYAMIDE, POLYETHERAMIDE AND THERMOPLASTIC ELASTOMER ALLOYS
ATE172721T1 (en) AMINO ACID DERIVATIVES AND THEIR USE AS ENKEPHALINASE INHIBITORS
EP0312913A3 (en) Treatment of illnesses with patelet-activating-factor antagonists and method therefor
DK730488D0 (en) SYNERGISTIC COMBINATION OF DECARBOXYLASE INHIBITORS AND L-DOPA PELLETS
ES2045366T3 (en) PROCEDURE FOR THE PREPARATION OF L-PHOSPHINOTRICINE.
ES2056333T3 (en) (QUINOLIN-2-IL-METOXI) SUBSTITUTED PHENYL-CARBONYL-UREAS.
EP0199888A3 (en) Control of heme and iron concentrations in body tissues
NZ220242A (en) Regulating fertility in cattle by administering epostane
ATE40795T1 (en) USE OF A CEREBRAL AND PERIPHERAL ANTHYPOXIDOTTIC.
Ip Hong Kong foreign students: Attitudes toward seeking psychological help
Lezak Neuropsychology by the Numbers.
Boila Amino acid metabolism by rumen papillae
Welch The effect of dietary protein concentration on zinc metabolism in ruminant Holstein calves
Humphries The training needs of parent educators
YU189887A (en) One-phase ferro-resonant transformer with assistant kernel
ES284886Y (en) PERFECTED BALL

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20040708